SpringWorks Therapeutics Valuation
| SWTXDelisted Stock | USD 46.99 0.00 0.00% |
At this time, the company appears to be overvalued. SpringWorks Therapeutics has a current Real Value of $37.27 per share. The regular price of the company is $46.99. Our model measures the value of SpringWorks Therapeutics from inspecting the company fundamentals such as Return On Equity of -0.52, shares outstanding of 75.35 M, and Operating Margin of (1.64) % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that SpringWorks Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of SpringWorks Therapeutics is based on 3 months time horizon. Increasing SpringWorks Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since SpringWorks Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SpringWorks Stock. However, SpringWorks Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.99 | Real 37.27 | Hype 46.99 | Naive 44.38 |
The intrinsic value of SpringWorks Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SpringWorks Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SpringWorks Therapeutics helps investors to forecast how SpringWorks stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SpringWorks Therapeutics more accurately as focusing exclusively on SpringWorks Therapeutics' fundamentals will not take into account other important factors: About SpringWorks Therapeutics Valuation
Our relative valuation model uses a comparative analysis of SpringWorks Therapeutics. We calculate exposure to SpringWorks Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SpringWorks Therapeutics's related companies.SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.
SpringWorks Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 74.1 M | |
| Forward Price Earnings | 322.5806 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in SpringWorks Stock
If you are still planning to invest in SpringWorks Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SpringWorks Therapeutics' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |